Patents by Inventor Sachin Lohani

Sachin Lohani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions of a peptide
    Patent number: 11471512
    Abstract: Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 18, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Himanshu Bhattacharjee, Suzanne M. D'Addio, Sachin Lohani, Sachin Mittal, Sergei Y. Pechenov, Daniel Hong Yin
  • PHARMACEUTICAL COMPOSITIONS OF A PEPTIDE
    Publication number: 20200276274
    Abstract: Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.
    Type: Application
    Filed: February 26, 2020
    Publication date: September 3, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Himanshu Bhattacharjee, Suzanne M. D'Addio, Sachin Lohani, Sachin Mittal, Sergei Y. Pechenov, Daniel Hong Yin
  • Pharmaceutical salts of an orexin receptor antagonist
    Patent number: 9969725
    Abstract: The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael McNevin, Sachin Lohani
  • PHARMACEUTICAL SALTS OF AN OREXIN RECEPTOR ANTAGONIST
    Publication number: 20170044149
    Abstract: The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 16, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Michael MCNEVIN, Sachin LOHANI
  • Process for producing bicycloaniline derivatives
    Patent number: 8507504
    Abstract: The present invention relates to a process for producing a hydrate of 3-(2,6-dichlorophenyl)-4-imino-7-[(2?-methyl-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-isoquinolin]-7?-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (Compound A) or of a pharmaceutically acceptable salt of Compound A and a crystalline form of Compound A or of a pharmaceutically acceptable salt of Compound A, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: August 13, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shuntaro Furukawa, Taketo Ikeno, Shinji Kato, Masashi Kawasaki, Hisaki Kojima, Wataru Minagawa, Naotaka Sawada, Fuyuki Yamamoto, Sachin Lohani, Yaling Wang
  • PROCESS FOR PRODUCING BICYCLOANILINE DERIVATIVES
    Publication number: 20110092520
    Abstract: The present invention relates to a process for producing a hydrate of 3-(2,6-dichlorophenyl)-4-imino-7-[(2?-methyl-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-isoquinolin]-7?-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (Compound A) or of a pharmaceutically acceptable salt of Compound A and a crystalline form of Compound A or of a pharmaceutically acceptable salt of Compound A, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.
    Type: Application
    Filed: June 2, 2009
    Publication date: April 21, 2011
    Inventors: Shuntaro Furukawa, Taketo Ikeno, Shinji Kato, Masashi Kawasaki, Hisaki Kojima, Wataru Minagawa, Naotaka Sawada, Fuyuki Yamamoto, Sachin Lohani, Yaling Wang
  • Crystalline forms of an HIV integrase inhibitor
    Publication number: 20080280945
    Abstract: Crystalline forms of a hexahydro-diazocinonaphthyridine trione compound are disclosed. The compound and its crystalline forms thereof are HIV integrase inhibitors useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset or progression of AIDS.
    Type: Application
    Filed: May 8, 2008
    Publication date: November 13, 2008
    Inventors: Sachin Lohani, Zhihui Peng, Arlene E. McKeown